ReviewJournal of cellular and molecular medicine2025
Harnessing Cellular Immunotherapy for EBV-Associated Malignancies: Current Advances and Future Directions.
Review in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- CRISPR-Engineered CAR-T Cell Therapy for Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma: A Review of Emerging Therapeutic Prospects.Reviews in medical virology · 2026Review
- Epstein-Barr Virus-Mediated Apoptosis Evasion in Epithelial Malignancies: Molecular Mechanisms and Therapeutic Implications.Biology · 2026Review
- Endobronchial Epstein-Barr Virus-Associated Smooth Muscle Tumor in Advanced HIV Infection: A Rare Case.The American journal of case reports · 2026Article
- Recent advances in Epstein-Barr virus vaccines development from mechanistic exploration to clinical translation.NPJ vaccines · 2026Review
- Beyond PD-1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next-Generation Immune Strategies.European journal of haematology · 2026Review
- Increased Frequency of the Chemokine Receptor CCR2 on Circulating CD19+CD5+ Lymphocytes in Therapy-Naïve CLL Patients With the Detectable EBV DNA and High-Avidity Antibodies Against the EBV Capsid Antigen.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Standard treatments for EBV-associated malignancies, such as chemotherapy and radiotherapy, demonstrate limited efficacy in relapsed or refractory cases, underscoring an urgent need for innovative therapeutic strategies. Recent advances in immunotherapy-particularly EBV-specific cytotoxic T lymphocytes and dendritic cell vaccines-have shown promise for both treatment and prevention. Engineered T cell therapies, including T-cell receptor (TCR) and chimeric antigen receptor (CAR) approaches targeting EBV antigens such as LMP1 and gp350, are progressing in clinical development. Compared to conventional intensive therapies, which often require prolonged administration and are associated with significant toxicity, cellular immunotherapy offers a favourable safety profile alongside robust in vivo T cell expansion and potent antitumor effects. Although preclinical and clinical trial results are encouraging, further refinement of therapeutic protocols is critical to enhance efficacy and improve access for diverse patient populations. In this review, we summarise the rationale for EBV-directed cellular therapies, outline their clinical applications to date, and discuss current limitations as well as emerging opportunities to optimise these strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.